XTAE
SOFW
Market cap155mUSD
Apr 29, Last price
1,603.00ILS
1D
-0.31%
1Q
-8.82%
IPO
-40.39%
Name
Sofwave Medical Ltd
Chart & Performance
P/E
—
P/S
260.70
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.02%
Rev. gr., 5y
192.63%
Revenues
60m
+18.56%
Net income
-5m
L-45.08%
CFO
-2m
L-62.00%
Profile
Sofwave Medical Ltd. develops an ultrasound technology for treating fine lines and wrinkles in Israel and internationally. It offers non-invasive skin treatment aesthetic medical devices to physicians. The company was incorporated in 2015 and is based in Yokne'am Illit, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 59,651 18.56% | 50,315 41.22% | 35,630 63.15% | ||||
Cost of revenue | 43,971 | 38,382 | 32,821 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 15,680 | 11,933 | 2,809 | ||||
NOPBT Margin | 26.29% | 23.72% | 7.88% | ||||
Operating Taxes | 490 | 16 | 321 | ||||
Tax Rate | 3.13% | 0.13% | 11.43% | ||||
NOPAT | 15,190 | 11,917 | 2,488 | ||||
Net income | (4,546) -45.08% | (8,278) -57.61% | (19,528) 186.08% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 326 | 4 | 30 | ||||
BB yield | -0.06% | 0.00% | -0.01% | ||||
| Debt | |||||||
Debt current | 609 | 562 | 594 | ||||
Long-term debt | 2,181 | 2,096 | 3,254 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (18,826) | (21,764) | (28,157) | ||||
| Cash flow | |||||||
Cash from operating activities | (2,396) | (6,306) | (10,694) | ||||
CAPEX | (277) | (407) | (447) | ||||
Cash from investing activities | 254 | 409 | (260) | ||||
Cash from financing activities | (620) | (1,723) | (1,347) | ||||
FCF | 14,570 | 12,261 | 1,805 | ||||
| Balance | |||||||
Cash | 21,616 | 24,422 | 32,005 | ||||
Long term investments | |||||||
Excess cash | 18,633 | 21,906 | 30,224 | ||||
Stockholders' equity | (58,025) | (53,477) | (34,182) | ||||
Invested Capital | 83,946 | 81,149 | 68,445 | ||||
ROIC | 18.40% | 15.93% | 6.83% | ||||
ROCE | 59.99% | 43.11% | 8.20% | ||||
| EV | |||||||
Common stock shares outstanding | 34,324 | 34,158 | 34,071 | ||||
Price | 15.36 11.95% | 13.72 66.91% | 8.22 -71.66% | ||||
Market cap | 527,219 12.50% | 468,647 67.34% | 280,064 -58.90% | ||||
EV | 508,393 | 446,883 | 251,907 | ||||
EBITDA | 17,467 | 13,438 | 3,928 | ||||
EV/EBITDA | 29.11 | 33.26 | 64.13 | ||||
Interest | 77 | 144 | 1,116 | ||||
Interest/NOPBT | 0.49% | 1.21% | 39.73% | ||||